Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Mesalamine products have been associated with interstitial nephritis and renal failure. Assess renal function before treatment and periodically thereafter. Limits and monitoring Reassess treatment if renal function worsens. Verify the exact oral or rectal delivery system. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 18, posted Aug 07, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Use metolazone cautiously in severe kidney disease. Discontinue if azotemia and oliguria worsen during treatment. Limits and monitoring Monitor fluid balance, potassium and other electrolytes as diuresis proceeds. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 3, posted Aug 08, 2016 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Bowel preparation in renal impairment warrants caution. Maintain adequate hydration and consider checking electrolytes, creatinine and BUN before and after the preparation. Limits and monitoring Review diuretics, renin-angiotensin system inhibitors and NSAIDs as potential contributors to renal risk. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 2, posted Oct 12, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Use caution with raloxifene in moderate or severe renal impairment because safety and efficacy have not been established in these groups. Limits and monitoring The cited evidence supplies no validated dose reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 32, posted Sep 02, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Bowel preparation in renal impairment warrants caution. Maintain adequate hydration and consider checking electrolytes, creatinine and BUN before and after the preparation. Limits and monitoring Review diuretics, renin-angiotensin system inhibitors and NSAIDs as potential contributors to renal risk. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 7, posted Oct 12, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Renal impairment categories as defined by the cited product label Renal action or finding Monitor renal function during extended-release tacrolimus treatment. Reduce the dose when nephrotoxicity or the monitored response warrants it. Limits and monitoring Confirm the exact ER capsule and trough target. Tacrolimus formulations have different dosing instructions. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 12, posted Feb 06, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding At CrCl 30-59 mL/min, exposure to thiotepa and its active metabolite TEPA may increase. Limits and monitoring Monitor toxicity. The finding does not supply a fixed percentage reduction. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 30, posted Feb 16, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
This summary uses the identified dated label. Verify the current label for this presentation before applying the regimen.
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The inhaled regimen requires no renal dose change. At CrCl below 60 mL/min, monitor more closely for anticholinergic effects from tiotropium. Limits and monitoring Confirm the device and ingredients. Review urinary retention, glaucoma symptoms and other anticholinergic medicines. Review 1 product or source caution
Verify the current prescribing information for this presentation.
DailyMed SPL version 3, posted May 18, 2020 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The inhaled regimen requires no renal dose change. At CrCl below 60 mL/min, monitor more closely for anticholinergic effects from tiotropium. Limits and monitoring Confirm the device and ingredients. Review urinary retention, glaucoma symptoms and other anticholinergic medicines. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted Aug 19, 2026 | Selected sections checked 2026-11-07. Independent clinical review pending.
Monitoring or toxicity
Renal measure Creatinine clearance (CrCl), mL/min Renal action or finding The inhaled regimen requires no renal dose change. At CrCl below 60 mL/min, monitor more closely for anticholinergic effects from tiotropium. Limits and monitoring Confirm the device and ingredients. Review urinary retention, glaucoma symptoms and other anticholinergic medicines. Review 1 product or source caution
Apply only to the stated formulation, indication and renal population.
DailyMed SPL version 16, posted Jul 16, 2025 | Selected sections checked 2026-11-07. Independent clinical review pending.
Return to top Find another drug
